- Home
- STEC vs SABS Comparison
STEC vs SABS Comparison
Compare STEC & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- SABS
- Stock Information
- Founded
- STEC 2006
- SABS 2014
- Country
- STEC China
- SABS United States
- Employees
- STEC N/A
- SABS N/A
- Industry
- STEC
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- STEC
- SABS Health Care
- Exchange
- STEC NYSE
- SABS Nasdaq
- Market Cap
- STEC 19.0M
- SABS 19.0M
- IPO Year
- STEC 2021
- SABS N/A
- Fundamental
- Price
- STEC $1.33
- SABS $1.19
- Analyst Decision
- STEC
- SABS Strong Buy
- Analyst Count
- STEC 0
- SABS 5
- Target Price
- STEC N/A
- SABS $11.40
- AVG Volume (30 Days)
- STEC 42.5K
- SABS 38.1K
- Earning Date
- STEC 04-08-2025
- SABS 05-19-2025
- Dividend Yield
- STEC N/A
- SABS N/A
- EPS Growth
- STEC N/A
- SABS N/A
- EPS
- STEC N/A
- SABS N/A
- Revenue
- STEC $260,474,693.00
- SABS $1,322,410.00
- Revenue This Year
- STEC $9.76
- SABS N/A
- Revenue Next Year
- STEC $15.85
- SABS $25.00
- P/E Ratio
- STEC N/A
- SABS N/A
- Revenue Growth
- STEC N/A
- SABS N/A
- 52 Week Low
- STEC $0.20
- SABS $1.11
- 52 Week High
- STEC $3.25
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- STEC 45.61
- SABS 31.84
- Support Level
- STEC $1.21
- SABS $1.11
- Resistance Level
- STEC $1.35
- SABS $1.80
- Average True Range (ATR)
- STEC 0.11
- SABS 0.16
- MACD
- STEC -0.04
- SABS -0.01
- Stochastic Oscillator
- STEC 12.12
- SABS 19.74
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.